Principal Financial Group (PFG) to pay $0.54 on Mar 29, 2019; Acadia Pharmaceuticals (ACAD) Shorts Raised By 0.79%

Principal Financial Group, Inc. (NASDAQ:PFG) Logo

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) had an increase of 0.79% in short interest. ACAD’s SI was 16.06M shares in February as released by FINRA. Its up 0.79% from 15.94 million shares previously. With 2.65 million avg volume, 6 days are for Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s short sellers to cover ACAD’s short positions. The SI to Acadia Pharmaceuticals Inc’s float is 16.44%. The stock decreased 0.36% or $0.08 during the last trading session, reaching $22.31. About 727,523 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 37.59% since February 14, 2018 and is downtrending. It has underperformed by 37.59% the S&P500. Some Historical ACAD News: 13/03/2018 Rep. Bruce Poliq: Acadia Harvesting and Boundary Disputes Bill Passes House, Led by Poliquin and Cosponsored by Pingree; 09/05/2018 – Acadia Pharma Presenting at Bank of America Conference May 15; 04/05/2018 – ACADIA PHARMACEUTICALS- REITERATES EXPECTATION TO END 2018 WITH MORE THAN $200 MLN OF CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES; 04/05/2018 – ACADIA PHARMACEUTICALS INC ACAD.O SEES FY 2018 SALES $255 MLN TO $270 MLN; 04/05/2018 – ACADIA PHARMA 1Q LOSS/SHR 44C, EST. LOSS/SHR 56C; 04/05/2018 – ACADIA Pharmaceuticals 1Q Loss/Shr 44c; 24/04/2018 – Lifshitz & Miller LLP Announces Investigation of Acadia Pharmaceuticals Inc., Allegiant Travel Company, Camping World Holdings,; 04/05/2018 – ACADIA Pharmaceuticals 1Q Loss $54.3M; 20/04/2018 – DJ ACADIA Pharmaceuticals Inc, Inst Holders, 1Q 2018 (ACAD); 27/04/2018 – ACADIA PHARM: 2 DATA SETS CONFIRM NUPLAZID IS WELL-TOLERATED

Principal Financial Group Inc (NASDAQ:PFG) is expected to pay $0.54 on Mar 29, 2019. (NASDAQ:PFG) shareholders before Mar 1, 2019 will receive the $0.54 dividend. Principal Financial Group Inc’s current price of $49.21 translates into 1.10% yield. Principal Financial Group Inc’s dividend has Mar 4, 2019 as record date. Jan 28, 2019 is the announcement. The stock increased 0.84% or $0.41 during the last trading session, reaching $49.21. About 1.69 million shares traded. Principal Financial Group, Inc. (NASDAQ:PFG) has declined 39.53% since February 14, 2018 and is downtrending. It has underperformed by 39.53% the S&P500. Some Historical PFG News: 30/05/2018 – PRINCIPAL FINANCIAL GROUP – ROBUSTWEALTH WILL REMAIN UNDER MANAGEMENT OF MIKE KERINS, CHIEF EXECUTIVE OFFICER, AS PART OF PRINCIPAL; 09/04/2018 – Principal Global CEO Sees a Trade War as Market Outlier (Video); 07/03/2018 – Principal® Kicks-Off National Effort to Boost Low Business Succession Planning; 14/05/2018 – Principal Financial at Barclays Insurance Forum Tomorrow; 14/05/2018 – Principal Financial Group Inc. Exits Encompass Health; 25/04/2018 – Principal® Innovates Underwriting Process to Help Break Down Barriers to Insurance Coverage; 03/04/2018 – Aflac Names J. Todd Daniels as EVP; Principal Financial Officer, Aflac Japan and Albert A. Riggieri as SVP, Global Chief Risk O; 25/04/2018 – Principal® lnnovates Underwriting Process to Help Break Down Barriers to Insurance Coverage; 09/03/2018 – GENOCEA BIOSCIENCES SAYS PENDING CONCLUSION OF CFO SEARCH, CEO WILLIAM CLARK TO ASSUME DUTIES OF PRINCIPAL FINANCIAL OFFICER – SEC FILING; 14/05/2018 – Principal Financial Group Inc. Exits Position in Sensata

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $3.20 billion. The firm offers NUPLAZID for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It currently has negative earnings. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder.

Investors sentiment decreased to 0.92 in Q3 2018. Its down 0.30, from 1.22 in 2018Q2. It fall, as 31 investors sold ACADIA Pharmaceuticals Inc. shares while 45 reduced holdings. 31 funds opened positions while 39 raised stakes. 116.41 million shares or 1.85% more from 114.30 million shares in 2018Q2 were reported. Balyasny Asset Management Ltd Liability Co holds 0.12% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 1.26 million shares. Nj State Employees Deferred Compensation Plan holds 0.11% or 32,000 shares in its portfolio. Jefferies Gru Lc owns 17,258 shares or 0% of their US portfolio. North Star Mgmt reported 880 shares stake. Swiss Bancorp owns 173,404 shares. Parallax Volatility Advisers Lp, California-based fund reported 793 shares. Morgan Stanley reported 260,255 shares or 0% of all its holdings. Citigroup has invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Tekla Mgmt Ltd Co holds 0.07% or 93,689 shares in its portfolio. Regions invested in 22 shares or 0% of the stock. Proshare Advsrs Limited Liability invested in 66,460 shares. Intll Grp stated it has 65,295 shares or 0% of all its holdings. Jpmorgan Chase And, New York-based fund reported 810,987 shares. Prudential Fincl Inc holds 0% or 11,500 shares. California Employees Retirement System reported 116,600 shares.

More notable recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: which released: “New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” on February 13, 2019, also with their article: “The Smartest People on Wall Street Are Buying These 3 Stocks — Should You? – Nasdaq” published on February 07, 2019, published: “Is a Beat in Store for Vertex (VRTX) This Earnings Season? – Nasdaq” on January 30, 2019. More interesting news about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were released by: and their article: “Acadia Pharmaceuticals Becomes Oversold (ACAD) – Nasdaq” published on December 20, 2018 as well as‘s news article titled: “MacroGenics Up on Lifting of Partial Hold on Cancer Candidate – Nasdaq” with publication date: January 28, 2019.

Among 6 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. ACADIA Pharmaceuticals had 8 analyst reports since August 23, 2018 according to SRatingsIntel. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Wednesday, October 10 by Bank of America. The rating was upgraded by PiperJaffray to “Overweight” on Friday, September 21. The rating was maintained by Cantor Fitzgerald on Tuesday, October 16 with “Overweight”. Cantor Fitzgerald maintained it with “Overweight” rating and $30 target in Thursday, November 1 report.

Since September 20, 2018, it had 2 insider buys, and 1 sale for $222.45 million activity. On Thursday, September 20 BAKER BROS. ADVISORS LP bought $22.65M worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 1.21 million shares. $200,041 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares were sold by Brege Laura.

More notable recent Principal Financial Group, Inc. (NASDAQ:PFG) news were published by: which released: “Principal Financial Group Q4 2018 Earnings Preview – Seeking Alpha” on January 28, 2019, also with their article: “Principal Financial -3.2% as Q4 oper EPS misses by 18 cents – Seeking Alpha” published on January 29, 2019, published: “Principal Financial (PFG) Q4 Earnings Miss, Revenues Top –” on January 30, 2019. More interesting news about Principal Financial Group, Inc. (NASDAQ:PFG) were released by: and their article: “Principal Financial Group declares $0.54 dividend – Seeking Alpha” published on October 25, 2018 as well as‘s news article titled: “Performance Food Group Company to Host Webcast of Second-Quarter Fiscal 2019 Results – Business Wire” with publication date: January 23, 2019.

Since September 4, 2018, it had 1 buy, and 5 sales for $153,870 activity. 1,000 shares were sold by LAWLER JULIA M, worth $50,170. $1.11M worth of Principal Financial Group, Inc. (NASDAQ:PFG) shares were sold by MCCAUGHAN JAMES P. GELATT DANIEL bought $1.20M worth of stock or 25,000 shares. Friedrich Amy Christine sold $44,100 worth of stock or 900 shares.

Principal Financial Group, Inc. provides retirement, asset management, and insurance services and products to businesses, individuals, and institutional clients worldwide. The company has market cap of $13.75 billion. It operates through Retirement and Income Solutions, Principal Global Investors, Principal International, and U.S. It has a 9.18 P/E ratio. Insurance Solutions divisions.

Principal Financial Group, Inc. (NASDAQ:PFG) Institutional Positions Chart